Eli Lilly and Company (LLY) — closed signal from October 23, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on January 21, 2026 — +31.8% at the close.
Predicted vs. what happened
What happened
Reached its target in 13 days.
The thesis — published October 23, 2025
Eli Lilly blends stability with growth, led by obesity and Alzheimer's treatments. Recent U.S. news points to a larger Alzheimer's market, and cash-flow math suggests the stock may be priced too low. Sales have grown about 18% a year over five years. Shares look washed out but the bigger trend still leans upward. Over the next 0-3 months, a steady climb is plausible as demand is clear and investors favor durable growers.
Primary drivers
- Growing U.S. Alzheimer's market expands the potential customer base
- Strong and rising demand for its obesity medicines keeps sales building
- Stock looks washed out while the recent trend still tilts upward
- Solid business results with investor views that are not overly hot
How it played out
LLY: target reached in 13 days
Lyra published LLY at $818.42 on 2025-10-23 for a short-term window ending 2026-01-21. The thesis expected 15% growth. It pointed to obesity and Alzheimer's treatments, a growing U.S. Alzheimer's market, strong obesity-medicine demand, a washed-out stock with an upward trend, and solid business results with investor views that were not overly hot.
Inside the window, LLY reached the $939.80 target in 13 days. It later peaked at $1133.95 on 2026-01-08, with a 38.6% peak gain. It ended the window at $1078.52. The thesis played out clearly.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.